Company Overview
Snapshot
Founded in January 2013, MetaboShield operates with 1–10 employees. The company is in the Pre-Funding stage. In May 2016, MetaboShield highlighted its technology offer, signaling its focus on innovative solutions for obesity.
Business overview
MetaboShield is developing an intestinal sleeve designed for permanent lodging in the small intestine via a non-surgical, anesthesia-free procedure. This semi-flexible device, placed at the end of the stomach, aims to facilitate weight loss and potentially aid in reversing Type 2 diabetes. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving the healthcare industry.
Strategic signal
In May 2016, MetaboShield presented its technology offer for a novel obesity solution. This signals the company's commitment to advancing non-invasive medical devices for chronic conditions, indicating a strategic focus on product development and market entry within the health tech landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is MetaboShield's core product?
- MetaboShield's core product is an insertable intestinal sleeve designed to be lodged permanently in the small intestine via the throat, offering a non-invasive solution for weight loss and Type 2 diabetes management.
- When was MetaboShield founded?
- MetaboShield was founded in January 2013.
- What is the primary medical application of MetaboShield's technology?
- MetaboShield's technology is primarily aimed at helping individuals with obesity shed weight and potentially reversing Type 2 diabetes through its intestinal sleeve.
- Where was MetaboShield developed?
- MetaboShield was developed by students at the Hebrew University of Jerusalem's Biodesign program in collaboration with team members at the Hadassah Medical Center in Israel.
- What was a key development for MetaboShield in 2016?
- In May 2016, MetaboShield showcased its technology offer for a new solution addressing obesity.